AstraZeneca presents new clinical data at the 2020 ASCO Virtual Scientific Program

By AstraZeneca | Jun 4, 2020


AstraZeneca presented new clinical data from its Phase 1a study with AZD4635, a next-generation immuno-oncology candidate, as a monotherapy and in combination with the PD-L1 antibody durvalumab (Imfinzi), in patients with advanced prostate cancer, at the 2020 ASCO Virtual Scientific Program (29-31 May 2020).

AZD4635 is a oral inhibitor of adenosine 2A receptor (A2AR) signaling discovered by Sosei Heptares and exclusively licensed to AstraZeneca in 2015.

Adenosine signaling is a normal process preventing autoimmunity that is co-opted by tumors as an immune escape mechanism. Pharmacologic blockade of signaling through A2aR may counteract the immunosuppressive effects of adenosine and allow for a more robust anti-tumor immune response in combination with immune checkpoint inhibitors.

Poster Summary

The poster (abstract #5518) was entitled “A phase I, open-label, multicenter study to assess the safety, pharmacokinetics, and preliminary anti-tumor activity of AZD4635 both as monotherapy and in combination in patients with advanced solid malignancies: results from prostate cancer patients (NCT02740985),” and reported the following:

  • In patients with advanced prostate cancer (mCRPC), AZD4635 alone or in combination with durvalumab was tolerable and associated with clinical benefit.
  • Retrospective analysis of Progression-Free Survival (PFS) shows that the clinical benefit is associated with high adenosine (ADO) gene expression signature in peripheral blood.
  • Analysis of patient peripheral blood provides evidence of immune activation.
  • Additional exploratory analysis of circulating tumor DNA (ctDNA) demonstrated several key altered pathways, which suggest potential combination strategies.
  • Additional studies are ongoing for AZD4635 in mCRPC and other tumor types.

View Abstract

View Poster

View Clinical Trial Information